Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 19
  1. May 14, 2026 · 07:00 · PRN · Routine +

    TULSA-PRO's Conference Glow Hides a Long Road to Profitability

    Profound to Showcase TULSA-PRO(TM), the TULSA Procedure(TM) and the Future of iMRI at AUA2026

    01
  2. May 14, 2026 · 07:00 · XRTX · Material −

    XORTX’s Deep-Discount Rescue Financing Signals Desperation as Biotech’s Cash Burn Leaves Investors Underwater

    XORTX Announces US$5 Million Public Offering

    02
  3. May 14, 2026 · 06:30 · FRX · Routine +

    Fennec Pharmaceuticals Q1 2026 Earnings

    Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

    03
  4. May 14, 2026 · 03:01 · VIVI · Material −

    Indian patent adds IP depth but revenue-sharing financing signals cash crunch

    TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product

    04
  5. May 13, 2026 · 19:10 · IOT · Routine +

    Innovotech Lands NRC Funding to Bolster Testing Services as Revenue Slump Drives Shares to Year Low.

    Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements

    05
  6. May 13, 2026 · 17:00 · APS · Neutral

    Hanmi Acquisition Delayed to May 2026 as Aptose Burns Cash Faster Than Expected

    Aptose Reports First Quarter 2026 Results

    06
  7. May 13, 2026 · 16:01 · MDNA · Routine −

    Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

    Medicenna Announces the Launch of a Marketed Public Offering of Securities

    07
  8. May 13, 2026 · 10:48 · PAIN · Routine +

    Vector Science Secures Manufacturing Access Amid Related-Party Scrutiny

    Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

    08
  9. May 13, 2026 · 10:12 · PHRM · Neutral

    PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots

    PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

    09
  10. May 13, 2026 · 10:08 · PHRM · Routine +

    PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

    Pharmadrug, Pharmather to explore PD-001 for hantavirus

    10
  11. May 13, 2026 · 09:00 · VPT · Routine +

    VentriPoint Diagnostics Secures China Regulatory Green Channel and Edison Gold, Yet Dilution Risks Loom

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    11
  12. May 13, 2026 · 08:51 · PHRX · Routine +

    Sairiyo Therapeutics Advances Hantavirus Pipeline Amidst Dilution and Debt Overhang

    PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

    12
  13. May 13, 2026 · 08:30 · SURE · Routine +

    SureNano Advances GLP-1 Pipeline Amidst Dilution Concerns and Clinical Milestones

    Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

    13
  14. May 13, 2026 · 08:30 · MBIO · Routine +

    MindBio Pivots to AI Voice Tech After Clinical Setback; Dilution Risks Loom

    Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities

    14
← Newer Older →